Diastereomer Impurity

A diastereomer impurity is the target sequence with inverted configuration at one or more alpha carbons. It forms when the activated amino acid loses its alpha proton before the amide bond is made, either through direct enolisation under base or through cyclisation to an oxazolone that racemises and then reopens. Because a peptide contains many stereocentres, inverting one gives a diastereomer rather than an enantiomer: a different compound with different physical properties, but the same formula and therefore the same mass.

Stepwise solid-phase synthesis resists this comparatively well because the urethane-type alpha-protecting group suppresses oxazolone formation. The residual risk concentrates in known places: cysteine and histidine racemise most readily under routine coupling conditions, and fragment condensation at any C-terminal residue other than glycine or proline is markedly worse. Oxime and benzotriazole additives, lower base loadings and shorter preactivation all reduce it.

The analytical consequence is what makes this class awkward. Mass spectrometry cannot see it at all, since formula and mass are unchanged, and reversed-phase chromatography resolves an epimer only sometimes. Finding it reliably requires hydrolysing the peptide and running chiral amino acid analysis. It is an impurity the two tests on almost every certificate are structurally incapable of detecting.

The resulting error is reading a confirmed mass and a high chromatographic purity as excluding stereochemical impurity, when both are compatible with several percent of a co-eluting epimer. The deeper mistake is treating configuration as a formality. D-residues are deliberately engineered into peptides because they change protease resistance and receptor binding; an accidental one is a pharmacologically distinct molecule, not a rounding error.